FilingReader Intelligence

Fosun Pharma gains approval for tenapanor, sodium picosulfate drugs

February 26, 2025 at 12:00 PM UTCBy FilingReader AI

Shanghai Fosun Pharmaceutical (HKEX: 2196) has announced regulatory approval for Tenapanor Hydrochloride Tablets, used to manage serum phosphorus levels in dialysis patients with chronic kidney disease, and Compound Sodium Picosulfate Granules, used for cleansing the colon prior to colonoscopies. The Tenapanor drug, licensed from Ardelyx, is marketed as 万缇乐® in mainland China, with the drug's approval indicating a contribution to treating irritable bowel syndrome with constipation in Hong Kong since November 2023. Shanghai Fosun's total investment in this drug's research and development amounts to approximately RMB 180 million as of January 2025. The company has invested approximately RMB 8.53 million into Compound Sodium Picosulfate Granules. Management anticipates that the approvals will enrich the company's product line.

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Shanghai Fosun Pharmaceutical (Group) Co publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →